Introduction
Hypofibrinogenemia due to disseminated intravascular coagulation (DIC)/hyperfibrinolysis is a common complication of acute promyelocytic leukemia (APL). [1] [2] [3] [4] [5] It was a frequent cause of serious bleeding before introduction of treatment with all-trans retinoic acid (ATRA). A coagulation disorder similar to that in APL may also occur in other FAB types of AML, but only a few data are available on the incidence in various FAB types, the risk of bleeding and the prognosis of these patients. 6, 7 We report on data of 379 patients with AML, seen in our institution between 1978 and 1997 in which coagulation studies were performed at diagnosis. We shall describe the clinical and laboratory characteristics of 19 patients with hypofibrinogenemia (fibrinogen level below 180 mg/dl) and compare them with 360 patients with normal fibrinogen (fibrinogen Ͼ180 mg/dl).
Materials and methods

Patients
Between 1978 and October 1997, 435 patients with the diagnosis of AML were admitted to our department. For this study the following patients were excluded: all patients with APL (n = 42) and patients in whom fibrinogen at diagnosis was not determined (n = 14).
Methods
AML were classified according to the FAB criteria. Immunophenotyping and cytogenetic analysis were done in most cases. The determination of PML-RAR alpha rearrangement was performed as previously described. 8 
Coagulation methods
Fibrinogen was determined according to Clauss. 9 Thrombin clotting time, thrombin time, partial thromboplastin time and reptilase time were performed according to standard procedures. The activity of clotting factors was determined by one-step clotting tests. Markers of coagulation and of fibrinolysis activation were determined by commercially available immunoassays: Fibrinopeptide A (radioimmunoassay; Imco, Byck-Mallinckrodt, Germany), thrombinantithrombin complexes and prothrombin fragment F1+2 (ELISA, Behringwerke, Germany), d-dimer (ELISA, Stago, France). Fibrinogen-fibrin degradation products (FDP) were determined according to the method of Merskey et al. 10 
Statistical methods
Comparison of laboratory parameters between the two groups was done with the Mann-Whitney U test. Overall survival and disease-free survival was determined by the Kaplan-Meier method. Patients who underwent bone marrow transplantation were censored at the time of transplantation.
Results
Prevalence of hypofibrinogenemia in FAB subgroups
The overall prevalence of hypofibrinogenemia (HF) in non-M3 leukemias was 5.0% (19 of 379 patients). With the exception of M7, HF was observed in all FAB subtypes (Table 1) . It was most common in patients with M5 (12.1%). Table 2 shows that there was no significant difference between patients with and without HF regarding age, sex, leukocyte count, hemoglobin, platelet count and LDH at diagnosis. Karyotyping was successful in 10 patients. Six patients had a normal karyotype, two patients +8 and two a complex karyotype. PML-RAR alpha was negative in all patients tested (n = 5). The FAB subtypes of the patients where karyotyping or PML-RAR alpha was not available were as follows: M2 three patients, M4 two patients and M5 three patients.
Clinical and laboratory characteristics of patients with hypofibrinogenemia
Coagulation abnormalities
Patients with HF had a significantly prolonged prothrombin time (PT) and thrombin clotting time (TCT) ( Table 2) . Moreover, they had slightly but significantly lower factor II and a markedly lower factor X activity ( Figure 1 ). There was no difference in factor V activity between both groups. Factor VIII activity was normal, but significantly lower than in patients without HF, in whom factor VIII activity was greatly increased (Figure 1 ). All patients with HF, in which these tests had been done, had markedly increased levels of coagulation (TAT, F1. 
Effect of induction therapy on fibrinogen level
In all but two patients, the fibrinogen level became normal after induction chemotherapy treatment. The median time for normalization (fibrinogen above 180 mg/dl) without replacement treatment was 5 days (Figure 3) . One of the two patients who did not normalize within 18 days died from cerebral hemorrhage at day 19 and the other was refractory to the first induction cycle, but his fibrinogen normalized after a successful second induction cycle.
Prognosis
Eleven (65%) out of 17 patients who had been treated with chemotherapy achieved a complete remission, four patients were resistant and two patients died during induction treatment (one of cerebral bleeding on day 19 after induction and the other from infection). The overall and the disease-free survival of patients with and without HF was not different (Figures 4 and 5 ).
Discussion
Infections and bleeding are the most common complications of induction therapy of acute myeloid leukemia. 3, 11, 12 The major reason for the bleeding tendency is the disease-and treatment-related thrombocytopenia. Hypofibrinogenemia is a well known and threatening complication of APL. 13, 14 When patients with APL are treated with chemotherapy, the coagulation defect worsens during the initial phase of therapy. 5, 15 As a result, fatal hemorrhages were quite common. Our data indicate that hypofibrinogenemia similar to that in APL may also occur in other types of acute myeloid leukemia. This observation has already been made in earlier studies which comprised, however, only a limited number of patients. 6, 7 In our study which included a large number of unselected patients, we show that approximately 5% of patients with M1-2 and M4-7 have a reduced level of fibrinogen at diagnosis. This prevalence is slightly lower than that reported in two previous small studies. Zuazo et al 6 found a prevalence of 9.2% (5/54) and Nur et al 7 of 7.3% (3/41). There is no universal agreement on how hypofibrinogene-
Figure 1
Box plots showing coagulation factors of non-M3 AML with or without hypofibrinogenemia at diagnosis. The square in the boxes shows the median, the bottom of the boxes marks the 25th percentile, the top of the boxes the 75th percentile. The bars mark the nonoutlier range.
Figure 2
Box plots showing markers of coagulation and fibrinolysis activation in non-M3 AML with or without hypofibrinogenemia at diagnosis. The square in the boxes shows the median, the bottom of the boxes marks the 25th percentile, the top of the boxes the 75th percentile. The bars marks the non-outlier range. mia should be defined in patients with AML. We have chosen a level of 180 mg/dl because this is the lower limit of the normal range in our laboratory. Others have used a cut-off level of 150 mg/dl or 200 mg/dl.
2,4,13 Most of our patients had fibrinogen levels well below 180 mg/dl. If we had chosen a cut-off level of 150 mg/dl the prevalence of hypofibrinogenemia would be only slightly less (4.5%).
The cause of hypofibrinogenemia in our patients was most likely DIC/hyperfibrinolysis. The level of activation markers of coagulation (FPA, TAT, F1.2) and of fibrinolysis (FDP, Ddimer) was markedly and significantly increased in comparison to AML patients with normal fibrinogen. During the time of this study, which extends over almost 20 years, the methods for the evaluation of activation of coagulation and fibrinolysis have changed (FPA and FDP in the earlier years and TAT, F1+2 and D-dimer during recent years). 16 Nevertheless, massive activation of the coagulation and fibrinolytic system could be documented in all cases. Therefore, we believe that the main reason for the low fibrinogen values was DIC/hyperfibrinolysis.
Figure 3
Proportion of patients with normalized fibrinogen over time after initiation of induction chemotherapy in non-M3 AML with hypofibrinogenemia (Kaplan-Meier method). The median time for normalization (fibrinogen above 180 mg/dl) without replacement treatment was 5 days.
Figure 4
Overall survival of non-M3 AML with or without hypofibrinogenemia (Kaplan-Meier method). The difference in survival between the groups is statistically not significant.
Figure 5
Disease-free survival of non-M3 AML with and without hypofibrinogenemia (Kaplan-Meier method). The disease-free survival was not different.
Among other coagulation abnormalities a modest, but highly significant decrease of factor X should be noted. This may be partly due to impairment of liver function, 17 but it may be also a specific effect since a reduction of other liversynthesized clotting factors was either not present (factor V) or less pronounced (factor II). It has been shown by Falanga et al 18 that monoblasts contain a factor X-activating enzyme which could be responsible for this specific factor X deficiency. We have described a patient with a marked factor X deficiency and DIC in APL which was closely associated with the course of leukemia. 19 Factor V and VIII deficiencies have been described in patients with AML and DIC. 20 There was no deficiency of factor V and VIII in our cases; however, the DIC patients has a significantly lower factor VIII value compared to non-DIC patients.
In order to find out which features of the leukemia are associated with hypofibrinogenemia we made a number of comparisons. There was a clear-cut, significantly higher prevalence of HF in patients with monoblastic leukemia which was not unexpected and in agreement with earlier observations. 6, 7 On the other hand, cases of HF were observed in all subtypes of AML except M7. Otherwise, there were no correlations to specific features of the leukemias. In particular, it was surprising that there was no correlation to the leukocyte count. Obviously, the occurrence of DIC is a specific feature of the leukemic cell and is not related to the tumor cell mass. When patients with APL and DIC were treated with chemotherapy alone (without ATRA) there was a high risk of early death (within 10 days) due to fatal bleeding. Rodeghiero et al 1 reported a 10% early hemorrhagic death rate in the GIMEMA studies. In contrast, no early death occurred in our non-M3 cases with HF, but one patient who remained hypofibrinogenic died from cerebral bleeding after day 10. This lower risk of fatal hemorrhage may be due to the fact that during chemotherapy fibrinogen recovered quickly (median time to normalization 5 days). In APL, the recovery of fibrinogen takes longer. Rodeghiero et al 1 found an unchanged fibrinogen value within 5 days of treatment and only a slight increase after 10 days.
A clinically important finding of our study is that the presence of DIC/hyperfibrinolysis with hypofibrinogenemia is not an adverse prognostic factor. The CR rate and the overall survival of these patients was not inferior to patients with normal fibrinogen. This is in contrast to patients with solid tumor and DIC/hyperfibrinolysis who have a very poor prognosis with no chance of cure.
In summary, it can be concluded from this study that: (1) DIC/hyperfibrinolysis with hypofibrinogenemia occurs in about 5% of non-M3 leukemias; (2) is most common in monoblastic leukemia; (3) resolves quickly during chemotherapy; (4) is not associated with the risk of early hemorrhagic death; and (5) is not a poor prognostic factor.
